4D Molecular Therapeutics, Inc.
NASDAQ:FDMT
5.04 (USD) • At close January 15, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | 2019 Q4 | 2019 Q3 | 2019 Q2 | 2019 Q1 | 2018 Q4 | 2018 Q3 | 2018 Q2 | 2018 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0.003 | 0.005 | 0.028 | -0.019 | 20.204 | 0.239 | 0.298 | 1.247 | 0.5 | 0.162 | 1.219 | 0.092 | 1.366 | 14.58 | 2 | -0.977 | 7.421 | 3.633 | 3.535 | 2.03 | 0.54 | 2.208 | 2.208 | 4.531 | 4.531 | 2.535 | 2.535 |
| Cost of Revenue
| 0 | 1.624 | 1.594 | 4.236 | 1.396 | 1.428 | 1.412 | 1.388 | 0.879 | 0.831 | 0.782 | 1.887 | 15.84 | 15.223 | 12.769 | 12.605 | 11.555 | 15.72 | 13.158 | 12.359 | 9.374 | 8.493 | 8.493 | 5.077 | 5.077 | 4.104 | 4.104 |
| Gross Profit
| 0.003 | -1.619 | -1.566 | -4.255 | 18.808 | -1.189 | -1.114 | -0.141 | -0.379 | -0.669 | 0.437 | -1.795 | -14.474 | -0.643 | -10.769 | -13.582 | -4.134 | -12.087 | -9.623 | -10.329 | -8.834 | -6.285 | -6.285 | -0.547 | -0.547 | -1.57 | -1.57 |
| Gross Profit Ratio
| 1 | -323.8 | -55.929 | 223.947 | 0.931 | -4.975 | -3.738 | -0.113 | -0.758 | -4.13 | 0.358 | -19.511 | -10.596 | -0.044 | -5.385 | 13.902 | -0.557 | -3.327 | -2.722 | -5.088 | -16.359 | -2.846 | -2.846 | -0.121 | -0.121 | -0.619 | -0.619 |
| Reseach & Development Expenses
| 38.484 | 31.86 | 27.87 | 26.028 | 25.066 | 23.584 | 22.412 | 21.5 | 18.94 | 20.422 | 19.381 | 17.528 | 15.84 | 15.223 | 12.769 | 12.605 | 11.555 | 15.72 | 13.158 | 12.359 | 9.374 | 8.493 | 8.493 | 5.077 | 5.077 | 4.104 | 4.104 |
| General & Administrative Expenses
| 12.651 | 10.601 | 10.294 | 10.605 | 9.112 | 8.791 | 7.992 | 8.467 | 8.055 | 8.166 | 8.23 | 7.328 | 8.187 | 6.953 | 5.543 | 6.84 | 3.682 | 3.062 | 3.654 | 5.959 | 3.052 | 2.442 | 2.442 | 1.985 | 1.985 | 1.099 | 1.099 |
| Selling & Marketing Expenses
| 0 | 0 | -1.594 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 12.651 | 10.601 | 8.7 | 10.605 | 9.112 | 8.791 | 7.992 | 8.467 | 8.055 | 8.166 | 8.23 | 7.328 | 8.187 | 6.953 | 5.543 | 6.84 | 3.682 | 3.062 | 3.654 | 5.959 | 3.052 | 2.442 | 2.442 | 1.985 | 1.985 | 1.099 | 1.099 |
| Other Expenses
| 0 | 0 | -0.01 | -0.011 | -0.158 | 2.52 | 1.424 | 0.003 | 0.009 | 0 | -0.046 | -0.007 | -0.013 | 0 | -0.101 | -0.129 | -0.021 | -0.018 | -0.013 | -0.045 | 0.007 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 51.135 | 42.461 | 36.57 | 36.633 | 34.178 | 32.375 | 30.404 | 29.967 | 26.995 | 28.588 | 27.611 | 24.856 | 24.027 | 22.176 | 18.312 | 19.445 | 15.237 | 18.782 | 16.812 | 18.318 | 12.426 | 2.446 | 2.446 | 1.988 | 1.988 | 1.097 | 1.097 |
| Operating Income
| -51.132 | -42.456 | -38.136 | -36.652 | -13.974 | -32.136 | -30.106 | -28.72 | -26.495 | -28.426 | -26.392 | -24.764 | -22.661 | -7.596 | -16.312 | -20.422 | -7.816 | -15.149 | -13.277 | -16.288 | -17.023 | -8.727 | -8.727 | -2.531 | -2.531 | -2.669 | -2.669 |
| Operating Income Ratio
| -17,044 | -8,491.2 | -1,362 | 1,929.053 | -0.692 | -134.46 | -101.027 | -23.031 | -52.99 | -175.469 | -21.651 | -269.174 | -16.589 | -0.521 | -8.156 | 20.903 | -1.053 | -4.17 | -3.756 | -8.024 | -31.524 | -3.952 | -3.952 | -0.559 | -0.559 | -1.053 | -1.053 |
| Total Other Income Expenses Net
| 7.289 | 7.503 | 5.735 | 4.369 | 3.718 | 2.52 | 1.424 | 1.341 | 0.804 | 0.34 | 0.054 | -0.319 | 0.422 | 0.007 | -0.094 | -0.125 | -0.017 | -0.004 | 0.117 | 0.173 | 0.348 | 0.469 | 0.469 | 0.349 | 0.349 | 0.076 | 0.076 |
| Income Before Tax
| -43.843 | -34.953 | -32.401 | -32.283 | -10.256 | -29.616 | -28.682 | -27.379 | -25.691 | -28.086 | -26.338 | -25.083 | -22.239 | -7.589 | -16.406 | -20.547 | -7.833 | -15.153 | -13.16 | -16.115 | -16.675 | -8.258 | -8.258 | -2.183 | -2.183 | -2.593 | -2.593 |
| Income Before Tax Ratio
| -14,614.333 | -6,990.6 | -1,157.179 | 1,699.105 | -0.508 | -123.916 | -96.248 | -21.956 | -51.382 | -173.37 | -21.606 | -272.641 | -16.28 | -0.521 | -8.203 | 21.031 | -1.056 | -4.171 | -3.723 | -7.938 | -30.88 | -3.74 | -3.74 | -0.482 | -0.482 | -1.023 | -1.023 |
| Income Tax Expense
| 0 | 0 | -0 | 6.728 | -3.876 | -1.428 | -1.424 | -0.106 | -1.599 | -0.68 | -0.154 | 0.312 | -0.435 | 0 | -0.007 | -0.004 | -0.004 | -0.014 | -0.13 | -0.218 | -0.341 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income
| -43.843 | -34.953 | -32.401 | -32.283 | -10.256 | -29.616 | -27.258 | -27.273 | -24.092 | -27.406 | -26.184 | -25.083 | -22.239 | -7.589 | -16.406 | -20.547 | -7.833 | -15.153 | -13.16 | -16.115 | -16.675 | -8.258 | -8.258 | -2.183 | -2.183 | -2.593 | -2.593 |
| Net Income Ratio
| -14,614.333 | -6,990.6 | -1,157.179 | 1,699.105 | -0.508 | -123.916 | -91.47 | -21.871 | -48.184 | -169.173 | -21.48 | -272.641 | -16.28 | -0.521 | -8.203 | 21.031 | -1.056 | -4.171 | -3.723 | -7.938 | -30.88 | -3.74 | -3.74 | -0.482 | -0.482 | -1.023 | -1.023 |
| EPS
| -0.79 | -0.63 | -0.66 | -0.83 | -0.24 | -0.77 | -0.83 | -0.84 | -0.74 | -0.85 | -0.81 | -0.93 | -0.82 | -0.28 | -0.61 | -0.77 | -0.36 | -1.02 | -0.89 | -1.09 | -1.12 | -1.61 | -1.61 | -0.43 | -0.43 | -0.52 | -0.52 |
| EPS Diluted
| -0.79 | -0.63 | -0.66 | -0.83 | -0.24 | -0.77 | -0.83 | -0.84 | -0.74 | -0.85 | -0.81 | -0.93 | -0.82 | -0.28 | -0.61 | -0.77 | -0.36 | -1.02 | -0.89 | -1.09 | -1.12 | -1.61 | -1.61 | -0.43 | -0.43 | -0.52 | -0.52 |
| EBITDA
| -49.429 | -40.832 | -36.542 | -35.139 | -12.578 | -30.708 | -28.694 | -27.332 | -25.616 | -27.595 | -25.61 | -22.877 | -22.279 | -7.226 | -15.931 | -20.051 | -7.447 | -14.79 | -12.933 | -15.97 | -11.606 | -8.524 | -8.524 | -2.353 | -2.353 | -2.498 | -2.498 |
| EBITDA Ratio
| -16,476.333 | -8,166.4 | -1,305.071 | 1,849.421 | -0.623 | -134.46 | -101.027 | -21.918 | -51.232 | -170.34 | -21.009 | -248.663 | -16.31 | -0.496 | -7.966 | 20.523 | -1.004 | -4.071 | -3.659 | -7.867 | -21.493 | -3.86 | -3.86 | -0.519 | -0.519 | -0.986 | -0.986 |